Can the anti-RIgG(HL)-N-MMAF ADC be used for in vivo applications?

Yes, the anti-RIgG(HL)-N-MMAF ADC is suitable for in vivo studies due to its stability and specific targeting. It is especially useful for preclinical models aimed at screening and evaluating rabbit monoclonal antibodies as potential ADC therapies.

How does MMAF in the anti-RIgG(HL)-N-MMAF ADC induce cell death?

MMAF, the cytotoxic component of the anti-RIgG(HL)-N-MMAF ADC, disrupts microtubule dynamics by binding to tubulin, which inhibits cell division and leads to apoptotic cell death. This mechanism is targeted specifically to cells that internalize the ADC.

What is the role of IgG in the structure and function of the anti-RIgG(HL)-N-MMAF ADC?

IgG antibodies, from which the anti-RIgG(HL)-N-MMAF ADC is derived, play a crucial role in immune response by binding to pathogens and their toxins. In the ADC, the IgG structure allows for specific binding to antigens, facilitating targeted delivery of the cytotoxic drug MMAF.

What are the implications of using the anti-RIgG(HL)-N-MMAF ADC for cancer research?

The anti-RIgG(HL)-N-MMAF ADC is a valuable tool for cancer research, offering a method to specifically target and kill cancer cells that express rabbit IgG receptors. Its use can help in the development of more effective and targeted cancer therapies.

What methodologies are recommended to monitor the therapeutic efficacy of the anti-RIgG(HL)-N-MMAF ADC in preclinical models?

To evaluate the therapeutic efficacy of the anti-RIgG(HL)-N-MMAF ADC in preclinical models, researchers should use a combination of in vivo imaging techniques to track tumor growth and regression, as well as histological analysis to assess apoptosis and necrosis at the cellular level.

Home
Products
Anti-Ab ADCs
IgG (H+L)
anti-RIgG(HL)-N-MMAF ADC

anti-RIgG(HL)-N-MMAF ADC (CAT#: ADC-AA-034)

This ADC product is comprised of an anti-rabbit IgG(H+L) specific polyclonal antibody conjugated via a noncleavable linker to MMAF. The antibody portion is a secondary antibody and the drug portion, MMAF, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rabbit monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG(H+L)

Overview
IgG antibody subtype is the most abundant serum immunoglobulins of the immune system, which is a protein complex composed of four peptide chains—two identical heavy chains and two identical light chains arranged in a Y-shape typical of antibody monomers. IgG is secreted by B cells and is found in blood and extracellular fluids and provides protection from infections caused by bacteria, fungi and viruses.

Overview
anti-rabbit IgG(H+L) specific polyclonal IgG antibody

Species Reactivity
Rabbit

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
MMAF (Monomethyl auristatin F)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-034. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

The anti-RIgG(HL)-N-MMAF ADC provided exceptional results in our monoclonal antibody development for rabbits, effectively targeting and disrupting microtubules

Excellent

Using anti-RIgG(HL)-N-MMAF has significantly accelerated our antibody screening process, showing no toxicity and high efficiency.

Excellent

The stability and effectiveness of the anti-RIgG(HL)-N-MMAF ADC make it a standout tool in our lab for pre-screening rabbit antibodies.

Excellent

We're impressed with how the anti-RIgG(HL)-N-MMAF ADC combines precision with safety, making it ideal for our cytotoxic studies.

Excellent

The anti-RIgG(HL)-N-MMAF ADC's ability to bind to IgG's heavy and light chains and induce cell death without primary toxicity is remarkable.

Q: 1: Can the anti-RIgG(HL)-N-MMAF ADC be used for in vivo applications?
A: Yes, the anti-RIgG(HL)-N-MMAF ADC is suitable for in vivo studies due to its stability and specific targeting. It is especially useful for preclinical models aimed at screening and evaluating rabbit monoclonal antibodies as potential ADC therapies.
Q: 2: How does MMAF in the anti-RIgG(HL)-N-MMAF ADC induce cell death?
A: MMAF, the cytotoxic component of the anti-RIgG(HL)-N-MMAF ADC, disrupts microtubule dynamics by binding to tubulin, which inhibits cell division and leads to apoptotic cell death. This mechanism is targeted specifically to cells that internalize the ADC.
Q: 3: What is the role of IgG in the structure and function of the anti-RIgG(HL)-N-MMAF ADC?
A: IgG antibodies, from which the anti-RIgG(HL)-N-MMAF ADC is derived, play a crucial role in immune response by binding to pathogens and their toxins. In the ADC, the IgG structure allows for specific binding to antigens, facilitating targeted delivery of the cytotoxic drug MMAF.
Q: 4: What are the implications of using the anti-RIgG(HL)-N-MMAF ADC for cancer research?
A: The anti-RIgG(HL)-N-MMAF ADC is a valuable tool for cancer research, offering a method to specifically target and kill cancer cells that express rabbit IgG receptors. Its use can help in the development of more effective and targeted cancer therapies.
Q: 5: What methodologies are recommended to monitor the therapeutic efficacy of the anti-RIgG(HL)-N-MMAF ADC in preclinical models?
A: To evaluate the therapeutic efficacy of the anti-RIgG(HL)-N-MMAF ADC in preclinical models, researchers should use a combination of in vivo imaging techniques to track tumor growth and regression, as well as histological analysis to assess apoptosis and necrosis at the cellular level.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-038	anti-RIgG(HL)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-036	anti-RIgG(HL)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-047	anti-Rat IgG(HL)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-035	anti-RIgG(HL)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-037	anti-RIgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-AA-018	anti-HIgG(Fab)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-001	anti-HIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-063	Anti-HIgG(Fab)-N-MMAF ADC	Noncleavable linkers	MMAF
ADC-AA-039	anti-Rat IgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-008	anti-HIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

CAT#	Product Name	Linker	Payload
ADC-W-604	Anti-FUT3-Mc-VC-PABC-MMAF ADC-3	MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)	MMAF (Monomethyl auristatin F)
ADC-AA-028	anti-MIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-W-493	Anti-CD19-Mc-MMAF ADC-3	Mc (maleimidocaproyl)	MMAF (Monomethyl auristatin F)
ADC-AA-019	anti-MIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-001	anti-HIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.